Page 38 - Gates-AnnualReport-2017

GATES BIOMANUFACTURING FACILITY
Gates Biomanufacturing Facility Staff (left to right) Rebecca Vartuli, Kaela Siahpush, Russell Marians, Sadhna Mehra, Deepa Vadakkan, Renee Jesser, Mitchell Fraller, Bailey Leadford, Sonja Giguere, Heather Clark, Tim Gardner, David Hahn, Frances Brostrom, Paul Lemaire, Jackie Nelson, Matt Seefeldt, Juan Mantalvo, Carter Sarah, Bertina Minjares, Graciela Gamez, Felicia Lanzarone, Christopher Freedman, Jaclyn Valentine, Debbie Keenan, Jessica Freeman, Saundra Jernberg, Tom Street
After providing process development services to both internal and external clients since opening in April 2015, the Gates Biomanufacturing Facility focused on having the quality systems and trained team in place to deliver its first clinical grade cell therapy products by the end of 2017.
With the recruitment of Terry J. Fry, M.D., one of the leading cancer researchers in the country, and the Investigational
NewDrug(IND)filingsofseveralofourcommercialclients, the GBF needed to recruit some key directors to better position itself for GMP operations. In July 2017, we recruited Ryan Crisman, PhD., the former Associate Director – Head of Late Stage Process Development at Juno Therapeutics. At Juno, Ryan led a cross-functional team responsible for development of commercial autologous CAR-T cell therapies for adult Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin’s
38 Gates Center for Regenerative Medicine